[Predictive value of conventional immuno-histochemical biomarkers in XXXX ].

@entity1 @entity5 @entity0
BACKGROUND: Pathological complete response (pCR) after neoadjuvant chemotherapy (NCT) in @entity0 ( @entity0 ) identifies @entity1 with good prognosis. AIM: To assess if the clinico-pathological subtype, determined by classic immunohistochemical (IHC) markers, is able to predict pCR and prognosis in @entity0 @entity1 treated with NCT. MATERIAL AND METHODS: One hundred thirty three @entity0 @entity1 aged 24-80 years, were treated with NCT. Clinico-pathological subtype was defined based on classic IHC markers. pCR was defined as the absence of invasive neoplastic cells in the breast and lymph nodes, on final breast surgery. RESULTS: pCR was achieved in 8.2% of @entity1 , 3.5 and 19.5% in luminal and hormonal receptor (HR) negative @entity5 respectively (p < 0.01). Median follow-up was 72.6 months (3.5-190). @entity1 who achieved pCR had higher overall survival (OS) (p = 0.04). A univariate analysis revealed that size of the @entity5 , ratio of metastatic to examined lymph nodes and absence of HR were significant predictors of pCR. These findings were not replicated in the multivariate analyses. CONCLUSIONS: Clinico-pathological subtypes were independent prognostic factors for pCR and OS in @entity0 @entity1 in our cohort. These findings support using classic and cheap biomarkers as a predictive tool for NCT in @entity0 .
